An interventional study of Electronic Cigarette in Smoking and Tobacco Use, sponsored by Medical University of South Carolina. Completed at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-11.
Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Smoking by Medical University of South Carolina — 8 open to participants now, 8 under way, none of them phase 3. Smoking · Medical University of South Carolina.
Among the 30 studies in Smoking by Medical University of South Carolina, this one is the 5th largest by enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2018, is one of 23 with no phase, and was the 14th registered.
1,510 studies on the registry are indexed under Smoking; 193 are open to participants now.
Browse Smoking studies →8 of the 30 studies in Smoking by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 21+ · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 21+ · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 21+ · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 21+ · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 21+
By country, each count listing its studies:
Of the 140 Smoking studies recruiting now, 74 (53%) set no upper age limit and 48 (34%) stop at 75 or younger; 3 take children under 18; 65 take healthy volunteers.
This study: 21 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3
First in 2008; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 638 is above the median of 115 across 1,165 interventional studies indexed under Smoking.
Median enrollment 99 across the 29 interventional studies, 117 across the 1 observational. Of the 22 that completed or were terminated, 17 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
Medical University of South Carolina is the lead sponsor of 874 studies on the registry; 165 are open to participants now.
Of its 131 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
3 of the studies in Smoking by Medical University of South Carolina that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05019495Medical University of South CarolinaOptimizing Tobacco Treatment Delivery for People Living With HIV | 2027-02-01 |
| NCT06373679Medical University of South CarolinaSwitch or Quit R01 | 2027-05-01 |
| NCT05896033Medical University of South CarolinaImpact of Cigarette and E-cigarette Menthol Regulation on Current Smokers of Menthol Cigarettes | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Smoking by Medical University of South Carolina, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure changes in smoking behavior during and following sampling of an e-cigarette product. E-cigarettes are classified by the US Food and Drug Administration (FDA) as a tobacco product, though they contain no tobacco. Unlike regular cigarettes, which are burned (creating smoke that is inhaled), e-cigarettes include a heating element that vaporizes nicotine. E-cigarettes are likely much safer than conventional cigarettes, but they may not be entirely safe. We are testing the effects of one specific ecigarette (NJoy) on naturalistic changes in smoking behavior. Neither the tobacco industry nor any ecigarette manufacturer provides support of any kind to this study. There is no requirement to quit smoking in this study, nor is there any requirement to use e-cigarettes.
Eligible smokers, once consented, will be randomized to receive a sample of ecigarettes (NJoy Pre-Filled Tank; n=440) or not (n=220). E-cigarette samples are inclusive of a battery and self-contained tanks of assorted flavors to last up to 4 weeks. Participants will be recruited nationally, but a subset (N=120) will be recruited locally to allow for biomarker collection . Our two-fold purpose is to 1) characterize naturalistic uptake of e-cigarettes, and 2) assess impact of e-cigarette uptake on smoking behavior. All smokers will be asked to provide smoking diary data, captured electronically, daily for 4 weeks. More substantive phone assessment will track smoking and related behaviors at baseline (Day 0) and +10, +17, and +24 days (weekly during initial 3 weeks, following brief lag for delays in product mailing), and at +1, +3, and +6 months.
Inclusion Criteria:
Participants will not receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
Participants will receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
Behavioral: Electronic Cigarette
An e-cigarette and four weeks of e-liquid provided to participants.
E-cig Use at End of Sampling Period
percentage of participants reporting using an e-cigarette
Time frame: at week 4
Conversion
Percentage of participants who purchase an e-cigarette or additional nicotine liquid on their own
Time frame: Study enrollment through end of 6-month follow up
Smoking Cessation
Point prevalence abstinence from conventional smoking
Time frame: at 6-month follow-up
| Milestone | Control | Sampling |
|---|---|---|
| Started | 211 | 427 |
| Completed | 211 | 427 |
| Not completed | 0 | 0 |
percentage of participants reporting using an e-cigarette
| percentage of participants | Control | Sampling |
|---|---|---|
| E-cig Use at End of Sampling Period | 13 | 72 |
Percentage of participants who purchase an e-cigarette or additional nicotine liquid on their own
| percentage of participants | Control | Sampling |
|---|---|---|
| Conversion | 20 | 19 |
Point prevalence abstinence from conventional smoking
| percentage of participants | Control | Sampling |
|---|---|---|
| Smoking Cessation | 8 | 14 |
Collected over study weeks 1 through 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control | 0/211 (0%) | 0/211 (0%) | 98/211 (46.4%) |
| Sampling | 0/427 (0%) | 1/427 (0.2%) | 177/427 (41.5%) |
| Event | Control | Sampling |
|---|---|---|
| asthma-induced hospitalizationRespiratory, thoracic and mediastinal disorders | 0/211 | 1/427 |
| Event | Control | Sampling |
|---|---|---|
| coughRespiratory, thoracic and mediastinal disorders | 43/211 | 73/427 |
| increased phlegmGastrointestinal disorders | 38/211 | 52/427 |
| headacheNervous system disorders | 17/211 | 52/427 |
| Age, Continuous(years) | Control | Sampling | Total |
|---|---|---|---|
| Mean | 42.0 ± 11.9 | 42.4 ± 11.2 | 42.2 ± 11.55 |
| Sex: Female, Male(Participants) | Control | Sampling | Total |
|---|---|---|---|
| Female | 120 | 222 | 342 |
| Male | 91 | 205 | 296 |
| Ethnicity (NIH/OMB)(Participants) | Control | Sampling | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 63 | 90 |
| Not Hispanic or Latino | 184 | 364 | 548 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Control | Sampling | Total |
|---|---|---|---|
| White | 146 | 291 | 437 |
| Black | 32 | 86 | 118 |
| Other | 33 | 50 | 83 |
| Motivation to Quit Smoking (0-10 scale)(units on a scale) | Control | Sampling | Total |
|---|---|---|---|
| Mean | 4.5 ± 3.1 | 4.3 ± 3.3 | 4.4 ± 3.2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2018 to primary completion in Sep 2022, 51 months.
Results were first posted in Sep 2023, 1 year after primary completion.
Of 402 non-industry interventional studies with no phase under Smoking, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 51 months is above that.
Counting every sponsor, half of 457 studies reached it within 23 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of South Carolina →